SYS-CON MEDIA Authors: Greg Ness, Elizabeth White, Glenn Rossman, Pat Romanski, Cynthia Dunlop

News Feed Item

Relburn-Metabolomics to Outline Clinical Development Plans for Lead Anti-Gout Product

Company to Present at Biotech Showcase 2014 in San Francisco

WESTFIELD, NJ -- (Marketwired) -- 01/08/14 -- Relburn-Metabolomics, Inc., an emergent life-science company focused on improving health for patients with metabolic disease, will present an update of the Company's scientific and clinical developments at the Biotech Showcase 2014 in San Francisco, CA. The overview will be presented by Relburn's Chairman and Chief Executive Officer, Dr. Raymond P. Warrell, Jr., on Tuesday, January 14, 2014 at 3:15 PM. Relburn's lead program is focused on the development of disease-transforming therapy for patients with chronic gout.

Unlike other anti-gout drugs, Relburn compounds exert bifunctional activities on both the production and excretion sides of the uric acid equilibrium. Excessive amounts of uric acid in blood are associated with acutely painful and destructive arthritis, along with renal insufficiency and accelerated cardiovascular disease. Inhibitors of the enzyme, xanthine oxidase (such as allopurinol) that reduce uric acid production are standard first-line treatments; however, less than half of patients achieve potentially beneficial "target" levels (i.e., ≤ 6.0 mg/dL). Other monofunctional drugs can increase urinary uric acid excretion, but these drugs are generally no more potent than allopurinol and are relegated to second-line, add-on use.

Based on clinical discoveries by Relburn scientists, the Company has developed a series of exceptionally potent bifunctional compounds that both reduce uric acid production as well as promote its excretion. In clinical trials encompassing more than 350 patients, serum uric acid was routinely reduced to levels < 1.0 mg/dL. Having established "clinical proof-of-concept," Relburn's Medicinal Chemistry program synthesized compound libraries with the objectives of elucidating mechanisms of action, enhancing clinical potency, and reducing potential side-effects. The Company has discovered a series of compounds that meet these objectives and that are covered by patent applications exclusively owned by Relburn. The Company is currently conducting IND-enabling studies and expects to initiate clinical trials in 2014. Alone among current investigational drugs, Relburn believes monotherapy with its compounds can potentially replace standard first-line treatments and meaningfully improve clinical outcomes for patients with chronic gout.

Further information about Relburn-Metabolomics, Inc. can be accessed here: www.relburn.com.

Information about the Biotech Showcase 2014 is available here: http://www.ebdgroup.com/bts/index.php

This press release may contain forward-looking statements with respect to business conducted by Relburn-Metabolomics, Inc. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Such forward-looking statements include those that express plan, anticipation, intent, contingency, goals, targets, or future developments and/or otherwise are not statements of historical fact. The words "potentially," "anticipates," "expects," and similar expressions also identify forward-looking statements. The Company does not undertake to update any forward-looking statements, and there are a number of factors that could cause actual results and developments to differ materially.

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
The 4th International DevOps Summit, co-located with16th International Cloud Expo – being held June 9-11, 2015, at the Javits Center in New York City, NY – announces that its Call for Papers is now open. Born out of proven success in agile development, cloud computing, and process automation, DevOps is a macro trend you cannot afford to miss. From showcase success stories from early adopters and ...
We live in a time when seconds – even milliseconds – can have a dramatic economic impact on your company’s future. With technology being the primary conduit for consumer interaction, the user experience is at center stage. User experience will be a deciding factor in separating the future winners from the losers. By building more speed and agility into the application delivery process, DevOps prom...
When an enterprise builds a hybrid IaaS cloud connecting its data center to one or more public clouds, security is often a major topic along with the other challenges involved. Security is closely intertwined with the networking choices made for the hybrid cloud. Traditional networking approaches for building a hybrid cloud try to kludge together the enterprise infrastructure with the public clou...
Ixia develops amazing products so its customers can connect the world. Ixia helps its customers provide an always-on user experience through fast, secure delivery of dynamic connected technologies and services. Through actionable insights that accelerate and secure application and service delivery, Ixia's customers benefit from faster time to market, optimized application performance and higher-qu...
SYS-CON Events announced today that Stratogent will exhibit at SYS-CON's 15th International Cloud Expo®, which will take place on November 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA. Stratogent is a custom managed services organization based in San Mateo, California. We design, implement, and support mission critical infrastructure 24x7 on premises, in datacenters and in t...
SYS-CON Events announced today that Harbinger Systems will exhibit at SYS-CON's 15th International Cloud Expo®, which will take place on November 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA. Harbinger Systems is a global company providing software technology services. Since 1990, Harbinger has developed a strong customer base worldwide. Its customers include software product...
SYS-CON Events announced today that Grid Dynamics, the leading provider of scalable eCommerce technology solutions, will exhibit at DevOps Summit Silicon Valley, which will take place on November 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA. Grid Dynamics is a leading provider of open, scalable, next-generation commerce technology solutions for Tier 1 retail. Grid Dynamics h...
SYS-CON Events announces a new pavilion on the Cloud Expo floor where WebRTC converges with the Internet of Things. Pavilion will showcase WebRTC and the Internet of Things. The Internet of Things (IoT) is the most profound change in personal and enterprise IT since the creation of the Worldwide Web more than 20 years ago. All major researchers estimate there will be tens of billions devices--co...
The only place to be June 9-11 is Cloud Expo & @ThingsExpo 2015 East at the Javits Center in New York City. Join us there as delegates from all over the world come to listen to and engage with speakers & sponsors from the leading Cloud Computing, IoT & Big Data companies. Cloud Expo & @ThingsExpo are the leading events covering the booming market of Cloud Computing, IoT & Big Data for the enterp...
Docker offers a new, lightweight approach to application portability. Applications are shipped using a common container format and managed with a high-level API. Their processes run within isolated namespaces that abstract the operating environment independently of the distribution, versions, network setup, and other details of this environment. This "containerization" has often been nicknamed "th...